Related Experiment Videos
Evaluation and management of dyslipoproteinemia in children
F A Franklin1, N Dashti, C C Franklin
1Department of Pediatrics, University of Alabama at Birmingham, USA.
Insights
Early management of dyslipidemia (DLP) in children is crucial for preventing atherosclerosis and cardiovascular disease (CVD) risk factors. Lifestyle changes are the primary treatment, with medications reserved for specific cases.
Area of Science:
- Pediatric Cardiology
- Preventive Medicine
- Lipid Metabolism
Background:
- Dyslipidemia in children (DLP) poses a significant risk for early atherosclerosis.
- Childhood intervention establishes lifelong healthy habits and mitigates cardiovascular disease (CVD) risk factors like obesity and smoking.
Purpose of the Study:
- To outline the evaluation and management strategies for pediatric dyslipidemia.
- To emphasize the importance of early lifestyle modifications in preventing long-term CVD.
Main Methods:
- Screening recommendations from the National Cholesterol Education Program (NCEP) for children with a family history of high cholesterol or early-onset CVD.
- Clinical evaluation based on low-density lipoprotein cholesterol (LDL-C) levels.
- Dietary interventions (Step 1 and Step 2 diets).
- Pharmacological therapy considerations for older children with persistent high LDL-C or additional CVD risk factors.
Main Results:
- Current NCEP screening guidelines exhibit low sensitivity in identifying all children with DLP.
- Dietary therapy is the initial treatment approach.
- Medications are typically reserved for older children meeting specific LDL-C thresholds or presenting with other CVD risk factors.
Conclusions:
- Effective management of pediatric dyslipidemia focuses on lifestyle modification for safe and sustained therapeutic outcomes.
- Early intervention is key to limiting atherosclerosis progression and establishing lifelong cardiovascular health.
- Current screening protocols may require refinement to improve sensitivity in detecting DLP in children.
Abstract:
The major goal of the evaluation and management of DLP in children is to provide safe and effective therapy with lifestyle modification. There is a strong rationale for the initiation of DLP treatment in childhood to limit the earliest stages of atherosclerosis, to establish lifelong lifestyle changes in diet and activity, and to limit the acquisition of additional CVD risk factors such as smoking and obesity. The NCEP has recommended screening for children with a parent with total cholesterol of 240 mg/dL or greater or a parent or grandparent with onset of CVD before age 55 years. Clinical evaluation and management are based on an LDL-C level of 130 mg/dL or greater. This approach to screening has a low sensitivity to identify children with DLP. Initial therapy is with a step 1 diet followed by the step 2 diet if necessary. Medications are reserved for older children with LDL-C of 190 mg/dL or greater after diet therapy or 160 mg/dL or greater with other CVD risk factors.